BLTE - CIK 0001889109
BELITE BIO, INC trades as BLTE and has a market capitalization of $5.47 B, making it the #1322 largest US-listed company by market value. This page tracks BELITE BIO, INC through 194 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| 6-K | - | 2026-05-20 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| Insider trade | 4 | 2026-05-08 |
| Insider trade | 4 | 2026-05-07 |
| Insider trade | 4 | 2026-05-06 |
| Insider trade | 4 | 2026-05-05 |
| Insider trade | 4 | 2026-05-04 |
| Insider trade | 4 | 2026-05-01 |
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update · Enrollment was completed with 530 subjects.
Belite expects to complete the new drug application submission in the second quarter of 2026 · Rolling submission initiated under Breakthrough ...
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”) today announced topline results ...
The largest companies sharing BELITE BIO, INC's SEC industry classification (pharmaceutical preparations).
BELITE BIO, INC (BLTE) has a market capitalization of $5.47 B as of 2026-06-10, ranking #1322 among US-listed companies.
In its latest fiscal year BELITE BIO, INC reported a net loss of $77.61M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.